EtimizolPutative nootropic drug CAS# 64-99-3 |
- Etomidate
Catalog No.:BCC1150
CAS No.:33125-97-2
- Etifoxine hydrochloride
Catalog No.:BCC1561
CAS No.:56776-32-0
- Acamprosate calcium
Catalog No.:BCC1327
CAS No.:77337-73-6
- Flumazenil
Catalog No.:BCC1259
CAS No.:78755-81-4
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 64-99-3 | SDF | Download SDF |
| PubChem ID | 6168 | Appearance | Powder |
| Formula | C9H14N4O2 | M.Wt | 210.23 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Antiffine; Ethimizole; Ethylnorantifein; Ethylnorantifeine; Ethylnorantiffeine; Ethymisol; Ethymisole; Etimizole | ||
| Solubility | Ethanol : ≥ 33.33 mg/mL (158.54 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 1-ethyl-4-N,5-N-dimethylimidazole-4,5-dicarboxamide | ||
| SMILES | CCN1C=NC(=C1C(=O)NC)C(=O)NC | ||
| Standard InChIKey | RYRFAMRQBZNEPX-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C9H14N4O2/c1-4-13-5-12-6(8(14)10-2)7(13)9(15)11-3/h5H,4H2,1-3H3,(H,10,14)(H,11,15) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Etimizol(Ethymisole; Antiffine; Ethylnorantifein) was shown to relieve amnesia effectively in the origin of which there is the hypoxic component (hypobaric hypoxia, actinomycin D, mechanical injury of the brain).
IC50 Value:
Target:
Etimizol has a catalytic effect on the respiratory center and belongs to the group of respiratory analeptics, however, it activates adrenokortikotropnuyu pituitary function, which leads to increased levels of glucocorticosteroids in the blood. There is also evidence that short etimizol improves memory and increases mental performance.
in vitro:
in vivo: The time interval between administration ofetimizol (3 mg/kg) and the onset of learning varied between 0.5 and 3 h in the several series. Etimizol did not facilitate the learning in rats whatever the time of administration and biological modality of reinforcement [1]. After administration of etimizol at doses of 10 or 1 mg/loop mean residence time of etimizol in the loop was 20.1 and 7.6 min, respectively, with mean standard deviation being 3.1 and 0.8, respectively [2]. Extracellular application of 5--10 mM/L etimizol exerted a specific effect on the giant neurons of the Coretus corneus isolated nervous system: action potential duration increased significantly, speed of development of its descending phase decreased, as well as the trace hyperpolarization amplitude [3]. References: | |||||
Etimizol Dilution Calculator
Etimizol Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.7567 mL | 23.7835 mL | 47.567 mL | 95.1339 mL | 118.9174 mL |
| 5 mM | 0.9513 mL | 4.7567 mL | 9.5134 mL | 19.0268 mL | 23.7835 mL |
| 10 mM | 0.4757 mL | 2.3783 mL | 4.7567 mL | 9.5134 mL | 11.8917 mL |
| 50 mM | 0.0951 mL | 0.4757 mL | 0.9513 mL | 1.9027 mL | 2.3783 mL |
| 100 mM | 0.0476 mL | 0.2378 mL | 0.4757 mL | 0.9513 mL | 1.1892 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Description: IC50 Value: N/A Etimizol was shown to relieve amnesia effectively in the origin of which there is the hypoxic component (hypobaric hypoxia, actinomycin D, mechanical injury of the brain). Etimizol has a catalytic effect on the respiratory center and belongs to the group of respiratory analeptics, however, it activates adrenokortikotropnuyu pituitary function, which leads to increased levels of glucocorticosteroids in the blood. There is also evidence that short etimizol improves memory and increases mental performance. in vitro: N/A in vivo: The time interval between administration ofetimizol (3 mg/kg) and the onset of learning varied between 0.5 and 3 h in the several series. Etimizol did not facilitate the learning in rats whatever the time of administration and biological modality of reinforcement [1]. After administration of etimizol at doses of 10 or 1 mg/loop mean residence time of etimizol in the loop was 20.1 and 7.6 min, respectively, with mean standard deviation being 3.1 and 0.8, respectively [2]. Extracellular application of 5--10 mM/L etimizol exerted a specific effect on the giant neurons of the Coretus corneus isolated nervous system: action potential duration increased significantly, speed of development of its descending phase decreased, as well as the trace hyperpolarization amplitude [3]. Toxicity: N/A Clinical trial: N/A
- Colchicine
Catalog No.:BCN6271
CAS No.:64-86-8
- Tolbutamide
Catalog No.:BCC5001
CAS No.:64-77-7
- Tetracycline Hydrochloride
Catalog No.:BCC1206
CAS No.:64-75-5
- Demeclocycline hydrochloride
Catalog No.:BCC5303
CAS No.:64-73-3
- Physostigmine hemisulfate
Catalog No.:BCC6724
CAS No.:64-47-1
- Lobeline Hydrochloride
Catalog No.:BCC8202
CAS No.:63990-84-1
- 13-Oxopodocarp-8(14)-en-18-oic acid
Catalog No.:BCN4009
CAS No.:63976-69-2
- Hopeyhopin
Catalog No.:BCN7533
CAS No.:63975-56-4
- Artemisinin
Catalog No.:BCN5814
CAS No.:63968-64-9
- (3R,10S)-Heptadeca-1,8-diene-4,6-diyne-3,10-diol
Catalog No.:BCC9111
CAS No.:63910-76-9
- VX-680 (MK-0457,Tozasertib)
Catalog No.:BCC2167
CAS No.:639089-54-6
- VUF 5681 dihydrobromide
Catalog No.:BCC7383
CAS No.:639089-06-8
- H-D-Val-OH
Catalog No.:BCC3145
CAS No.:640-68-6
- Paroxetine maleate
Catalog No.:BCC7265
CAS No.:64006-44-6
- Tamgermanetin
Catalog No.:BCN7944
CAS No.:640235-90-1
- 4(15)-Oppositene-1,7-diol
Catalog No.:BCN4180
CAS No.:640289-58-3
- Torachrysone 8-O-glucoside
Catalog No.:BCN4181
CAS No.:64032-49-1
- Boc-Lys(Ac)-OH
Catalog No.:BCC3411
CAS No.:6404-26-8
- Boc-Nle-OH
Catalog No.:BCC3296
CAS No.:6404-28-0
- Boc-ε-Acp-OH
Catalog No.:BCC3205
CAS No.:6404-29-1
- Z-D-Pro-OH
Catalog No.:BCC2752
CAS No.:6404-31-5
- Ro 04-5595 hydrochloride
Catalog No.:BCC7234
CAS No.:64047-73-0
- GANT 58
Catalog No.:BCC1587
CAS No.:64048-12-0
- Cannabispirol
Catalog No.:BCN4609
CAS No.:64052-90-0
[Different therapeutic approaches for chronic diffuse liver lesions using ornicetil, lactulose, etimizol and corinfar].[Pubmed:12073265]
Lik Sprava. 2002;(2):64-8.
Different therapeutic regimens were tried in 67 patients with hepatic cirrhosis and in 54 patients with chronic hepatitis depending on the leading pathological syndrome. Treatment schemes involved the use of the drug ornicetil in patients having acute episodes of portal systemic encephalopacy, lactulose in those presenting with an increased content of ammonia in the blood and symptoms of chronic portal systemic encephalopacy; Etimizol was given to those patients with an apperant antioxidant imbalance. Differentiated approaches to the institution of curative measures permitted improving considerably the patients' medical rehabilitation, achieving regression of pathological manifestations. It has been found out that the above drugs exert a positive effect on the cytolytic and mesenchimal-inflammatory syndromes and will, we believe, come to be widely used for treating diffuse lesions of the liver.
[The spectrophotometric determination of metronidazole and etimizol when jointly present in the urine].[Pubmed:8848799]
Sud Med Ekspert. 1995 Oct-Dec;38(4):27-9.
A method for spectrophotometric measurement of metronidasole and ethymisole jointly present in the urine has been developed. Combined polynomes have been designed to eliminate the effects of light-absorbing admixtures extracted from the urine on the results of analysis.
[The effect of etimizol on the functional status of the blood coagulation systems and fibrinolysis in workers on expedition-duty watches working under the climatic conditions of northern Tyumen Province].[Pubmed:7663295]
Eksp Klin Farmakol. 1995 May-Jun;58(3):40-2.
The study was undertaken to reveal the effects of ethymisole on the functional status of blood coagulation and fibrinolytic systems, the body's adaptative reserves of workers from expeditionary-duty teams. Ethymisole was found to normalize the functional status of blood coagulation and fibrinolytic systems, to restore conjunction of their functioning. The use of the drug was ascertained to normalize the activity of lipid peroxidation products, to enhance the adaptative reserves of expeditionary-duty workers by prolonging the resistance phase. It is concluded that ethymisole may be used as an agent that enhances the body's adaptative reserves.
